Company Overview and News

 
The MnM Portfolio, September 2018 - Marking My 100th SA Article, And Revisiting The First

2018-10-16 seekingalpha
This month’s article marks the forty-third installment in my ongoing series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for “Minne(sota) ‘n Monthly.”
UNM VIG O FSC OPRF OSLE OCSL FSCFL STAG FSCE

2
Main Street Capital's Detailed Dividend Sustainability Analysis (Includes First Half Of 2019 Special Periodic Dividend Projection)

2018-10-15 seekingalpha
Following continued requests, this article analyzes MAIN’s dividend sustainability by performing three tests based on recent historical and projected future quarterly results.
AIY AINV FSIC MAIN MCQ AIB MCV OSLE PSEC OCSL MSCA.CL MCX SLRC MSCA TWO PBB SLRA MCC

 
Oaktree Specialty Lending Corporation Schedules Fourth Fiscal Quarter and Full Year 2018 Earnings Conference Call for November 29, 2018

2018-10-11 globenewswire
LOS ANGELES, CA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Oaktree Specialty Lending Corporation (NASDAQ:OCSL) (“Oaktree Specialty Lending”) today announced that it will report its financial results for the fourth fiscal quarter and full year ended September 30, 2018 before the opening of the Nasdaq Global Select Market on Thursday, November 29, 2018. Management will host a conference call to discuss the results on the same day at 11:00 a.
OCSL OSLE

30
Why I Sold This 11.1% Yielding BDC That Could Now Be A 'Buy'

2018-10-11 seekingalpha - 5
FSIC was my smallest position and I sold before the recent declines for the reasons discussed in this article.
CCT AIY AINV CLA SDRPQ MCQ HRZN HTF KAP BKCC MCV BBDC OSLE MM ACTPF KCAP ABDC HTFA TSG CPTA FDMCF AST MCC GSBD HDSN TCRX GARS HCAPL MMCC FSIC TCPC AIB TCRD TCRZ PSEC SD TSLF OCSI SDOCQ OCSL MCX HCAP SDRXP PBB SDRXQ

1
IX vs. OCSL: Which Stock Is the Better Value Option?

2018-10-08 zacks
Investors interested in stocks from the Financial - Miscellaneous Services sector have probably already heard of Orix (IX - Free Report) and Oaktree Specialty Lending (OCSL - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
OCSL IX OSLE

3
Top Ranked Income Stocks to Buy for October 5th

2018-10-05 zacks
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 5th:
OCSL ODP PAG WYND

8
This Stable 10.1% Yielding BDC Is A Strong Buy At These Levels

2018-10-04 seekingalpha
TCPC is a higher quality BDC and is currently trading lower (below book value) for the reasons discussed in this article.
AIY AINV GAIN HTF KAP BKCC PFLT BBDC OSLE KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD PSEC NMFC TSLF MCX HCAP PBB CLA MCQ GAINM HRZN PNNT MCV GADDP CGBD HTGZ MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA

2
24 Safer Monthly-Dividend-Paying October Equities From Your Dividend Dogcatcher

2018-10-02 seekingalpha
24 of 87 monthly paying (MoPay) U.S. dividend stocks were tagged "safer" by showing positive annual returns and free cash flow yields greater than their dividend yields, as of 9/27/18.
AGNCB WPTIF CMLEF APLE O BTBIF FSC OPRF ORC OSLE SJT OCSL FSCFL GHIFF AGNCP AGNC STAG FSCE

2
Oaktree Specialty Lending Sees Hammer Chart Pattern: Time to Buy?

2018-10-01 zacks
Oaktree Specialty Lending Corp. (OCSL - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because OCSL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
OCSL VZ OSLE VZA

3
Oaktree Specialty Lending: Worth The Risk?

2018-09-27 seekingalpha
OCSL was such a train wreck that one of the first things the new management team did was change the name.
ARU OCSL MSCA.CL FSAM ARCC MSCA MAIN PBB OSLE PSEC

5
Prospect Capital's Detailed Dividend And NAV Sustainability Analysis - Part 2 (Includes Remaining Fiscal Year 2019 Monthly Dividend Projection)

2018-09-27 seekingalpha
Part 2 of this article discusses two topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).
AIY AINV GAIN MCQ GAINM MCV PFLT OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK TRI NEWTL PBB

 
Euronet Worldwide's (EEFT) ATM Business to Aid Revenue Growth

2018-09-26 zacks
Euronet Worldwide, Inc. (EEFT - Free Report) is an industry leader in providing secure electronic financial transactions for financial institutions. The company’s extensive ATM network includes more than 37,000 ATMs all over the world. Euronet continues to see plenty of opportunities to deploy ATMs across its existing markets as well as new markets. Over the last year, the company has grown its ATM base by 14% and still has thousands of ATMs in the pipeline.
MGI OCSL EEFT PJT OSLE

61
10 Best Stocks Under $10

2018-09-20 investorplace
Good things come in small packages goes the saying. Nowhere is that truer than in the markets where stocks under $10 grow to be $100 and possibly even $1,000 over time.
REG FCR.DB.H FCR.DB.I WETF BXG VAC FCR.DB.J AY DXJ FSC GZT OAK HEDJ OSLE JILL SIRI ARCO AMZN FCR.DB.E MCD BBX IBN AQN OCSL FCRGF GZT ICICIBANK FSCFL EDE 532174 FCAP FCR TRVG FSCE

8
Potentially Oversold Best Of Breed BDC: Initiating Coverage

2018-09-19 seekingalpha
Earlier this year, I initiated active coverage of GAIN (8.2% yield) and its preferred stocks GAINM (6.2% yield) and now its newly issued GAINL (6.3% yield).
AIY AINV CLA GAIN GAINM MCQ KAP PNNT BKCC MCV PFLT OSLE GADDP GAINL GLADO HTGZ KCAP GLAD ABDC MSCA CPTA MCC TCRX ARCC HCAPL FSIC MAIN TCPC AIB TCRD TCRZ PSEC HTGX NMFC HTGY TSLF OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA

8
Approaching Oversold Conditions, Driving 9% Yield With Upcoming Specials

2018-09-13 seekingalpha - 1
I recently purchased additional shares of this higher quality BDC that's trading 6% below book value paying a 9% dividend yield with an upcoming special dividend in Q4.
AIY AINV CLA MCQ KAP PNNT BKCC MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC CPTA MCC TCRX ARCC HCAPL FSIC TCPC AIB TCRD TCRZ PSEC HTGX NMFC TSLF HTGY OCSI ARU OCSL MCX HCAP SUNS HTGC PBB PNTA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 31678A103